Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VRC 01 mRNA

Drug Profile

VRC 01 mRNA

Alternative Names: VRC-HIVMAB01060-00-AB; VRC01; VRC01 mRNA-LNP

Latest Information Update: 08 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Acuitas Therapeutics
  • Developer Acuitas Therapeutics; South East Asia Research Collaboration in HIV; University of Pennsylvania
  • Class Antiretrovirals; Antivirals; Monoclonal antibodies; RNA
  • Mechanism of Action Gene transference; HIV antigen inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 08 Dec 2022 No development reported - Phase-II for HIV-1 infections (Adjunctive treatment) in Thailand (IV) (Acuitas Therapeutics website, December 2022) (South East Asia Research Collaboration in HIV website, December 2022)
  • 12 Feb 2022 Efficacy data from a phase-II clinical trials in HIV-1 infections presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)
  • 28 May 2020 No recent reports of development identified for preclinical development in HIV-1-infections(Prevention) in Canada (IV, Infusion)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top